Methysergide-Induced Valvular Heart Disease: A Report of 2 Cases
DOI:
https://doi.org/10.1532/HSF98.20061047Abstract
Methysergide is a serotonin antagonist and is used as a long-term prophylactic treatment for migraine. Although many patients experience adequate control of migraine episodes, methysergide has been reported to cause retroperi-toneal and pleuropulmonary fibrosis. Cardiovascular side effects mainly in the form of valvular fibrosis have been less recognized. We report 2 cases of methysergide-related mitral valve fibrosis.References
Bana DS, MacNeal, PS, LeCompte PM, Shah Y, Graham JR. 1974. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88: 640-55.nGraham JR. 1964. Methysergide for prevention of headaches. N Eng J Med 270: 67-72.nMason JW, Billingham ME, Friedman JP. 1977. Methysergide induced heart disease. A case of multivalvular and myocardial fibrosis. Circulation 56: 889-90.nMisch KA. 1974. Development of heart valve lesions during methysergide therapy. British Medical Journal 2: 365-6.nPritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. 2002. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77: 1280-6.nRedfield MM, Nicholson WJ, Edwards WD, Tajik AJ. 1992. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med117:50-2.n
